{
    "nctId": "NCT00654836",
    "briefTitle": "Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer",
    "officialTitle": "A Phase II Study of Carboplatin, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Avastin as the First Line Therapy in Metastatic Breast Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 32,
    "primaryOutcomeMeasure": "Progression-free Survival",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed primary adenocarcinoma of the breast\n\n  * Locally recurrent or metastatic disease\n* Must have HER-2-negative breast cancer or, if HER-2-positive, must be unable to receive trastuzumab (Herceptin\u00ae) or have previously received trastuzumab in the past\n* Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as \\> 20 mm by conventional techniques or as \\> 10 mm by spiral CT scan.\n* No known CNS disease\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\nInclusion criteria:\n\n* Postmenopausal status not specified\n* ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%\n* Life expectancy \\> 12 weeks\n* WBC \u2265 3,000/mcL\n* Absolute neutrophil count \u2265 1,500/mcL\n* Platelet count \u2265 100,000/mcL\n* Total bilirubin normal\n* AST and ALT \u2264 2.5 times upper limit of normal (ULN)\n* Alkaline phosphatase \u2264 2.5 times ULN (unless bone metastasis is present in the absence of liver metastasis)\n* Creatinine \u2264 1.5 mg/dL\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No other concurrent malignancies within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix\n\nExclusion criteria:\n\n* Pre-existing neuropathy \u2265 grade 1\n* Uncontrolled intercurrent illness including, but not limited to, any of the following:\n\n  * Ongoing or active infection\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n  * Serious, non-healing wound, ulcer, or bone fracture\n  * Psychiatric illness/social situations that would limit compliance with study requirements\n* Inadequately controlled hypertension (defined as systolic blood pressure \\> 150 mm Hg and/or diastolic blood pressure \\> 100 mm Hg on antihypertensive medications)\n* History of hypertensive crisis or hypertensive encephalopathy\n* New York Heart Association class II-IV congestive heart failure\n* History of myocardial infarction or unstable angina within the past 6 months\n* History of stroke or transient ischemic attack within the past 6 months\n* Significant vascular disease (e.g., aortic aneurysm, aortic dissection)\n* Symptomatic peripheral vascular disease\n* Evidence of bleeding diathesis or coagulopathy\n* Significant traumatic injury within the past 28 days\n* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months\n* Proteinuria, as demonstrated by either urine protein:creatinine ratio \u2265 1.0 OR urine dipstick for proteinuria \u2265 2+\n\n  * Patients discovered to have \u2265 2+ proteinuria on dipstick urinalysis at baseline must demonstrate 24-hour urine protein \u2264 1g\n* History of allergy or hypersensitivity to paclitaxel albumin-stabilized nanoparticle formulation, paclitaxel, bevacizumab, carboplatin, albumin, drug product excipients, or chemically similar agents\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Recovered from all prior therapy\n* No prior chemotherapy for locally recurrent or metastatic disease\n* Prior neoadjuvant or adjuvant chemotherapy allowed\n* More than 1 week since prior core biopsy or other minor surgical procedure, excluding placement of a vascular access device\n* More than 4 weeks since prior and no concurrent major surgical procedure or open biopsy\n* More than 4 weeks since prior radiotherapy\n* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)\n* At least 1 year since prior taxane regimen\n* No other concurrent investigational agents\n* Concurrent anticoagulation allowed, provided the following criteria are met:\n\n  * Stable dose of warfarin or low molecular weight heparin\n  * INR within desired range (2-3)\n  * No evidence of active bleeding or coagulopathy\n* No concurrent combination antiretroviral therapy for HIV-positive patients\n* No other concurrent radiotherapy, chemotherapy, immunotherapy, or antitumor hormonal therapy",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}